A groundbreaking study published in the European Heart Journal reveals the successful development of an advanced artificial intelligence (AI) model for screening cardiac amyloidosis, a severe heart condition characterized by abnormal protein buildup affecting heart function. Researchers from the Mayo Clinic and Ultromics, Ltd. designed this AI tool to analyze routine echocardiograms, achieving impressive accuracy rates of 85% for identifying patients with cardiac amyloidosis and 93% for ruling it out. This innovative model simplifies diagnosis, reducing the need for extensive testing and enabling earlier treatment—crucial for improving patient outcomes. With the support of 17 hospitals globally, the AI’s superior performance compared to traditional clinical scoring methods emphasizes its potential as a transformative tool in cardiology. Now FDA-cleared, the AI model is rolling out in hospitals nationwide, offering an efficient solution that integrates seamlessly into standard cardiac care practices, enhancing diagnostic accuracy and patient management.
Share
Read more